NASDAQ:VNDAVanda Pharmaceuticals Stock Price, Forecast & News

Vanda Pharmaceuticals' stock was trading at $10.60 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, VNDA stock has increased by 8.1% and is now trading at $11.46. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vanda Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Vanda Pharmaceuticals.

Vanda Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Vanda Pharmaceuticals.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) posted its quarterly earnings data on Wednesday, May, 6th. The biopharmaceutical company reported $0.01 EPS for the quarter, hitting analysts' consensus estimates of $0.01. The biopharmaceutical company earned $58 million during the quarter, compared to analyst estimates of $57.53 million. Vanda Pharmaceuticals had a return on equity of 30.60% and a net margin of 49.12%. View Vanda Pharmaceuticals' earnings history.

Vanda Pharmaceuticals updated its FY 2020 After-Hours earnings guidance on Wednesday, May, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $240-260 million, compared to the consensus revenue estimate of $247.77 million.

4 Wall Street analysts have issued 1-year price targets for Vanda Pharmaceuticals' stock. Their forecasts range from $12.00 to $25.00. On average, they anticipate Vanda Pharmaceuticals' stock price to reach $16.00 in the next twelve months. This suggests a possible upside of 39.6% from the stock's current price. View analysts' price targets for Vanda Pharmaceuticals.

Media coverage about VNDA stock has trended neutral recently, according to InfoTrie. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Vanda Pharmaceuticals earned a daily sentiment score of 0.4 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View the latest news aboutVanda Pharmaceuticals.

Vanda Pharmaceuticals saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 4,320,000 shares, a decline of 6.3% from the April 30th total of 4,610,000 shares. Based on an average daily volume of 791,600 shares, the short-interest ratio is currently 5.5 days. Currently, 8.3% of the shares of the stock are short sold. View Vanda Pharmaceuticals' Current Options Chain.

Some companies that are related to Vanda Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), Sangamo Therapeutics (SGMO), Zogenix (ZGNX), NVIDIA (NVDA), Array Biopharma (ARRY), Micron Technology (MU), Exelixis (EXEL) and ImmunoGen (IMGN).

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

Vanda Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.69%), State Street Corp (5.20%), Acadian Asset Management LLC (2.14%), Nuveen Asset Management LLC (1.47%), Geode Capital Management LLC (1.40%) and Bank of New York Mellon Corp (1.11%). Company insiders that own Vanda Pharmaceuticals stock include Gian Piero Reverberi, James Patrick Kelly, Mihael Hristos Polymeropoulos, Richard W Dugan and Timothy Williams. View institutional ownership trends for Vanda Pharmaceuticals.

VNDA stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., BlackRock Inc., Two Sigma Investments LP, Nuveen Asset Management LLC, Wells Fargo & Company MN, Parametric Portfolio Associates LLC, UBS Group AG, and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have sold Vanda Pharmaceuticals company stock in the last year include Gian Piero Reverberi, James Patrick Kelly, Mihael Hristos Polymeropoulos, Richard W Dugan, and Timothy Williams. View insider buying and selling activity for Vanda Pharmaceuticals.

VNDA stock was purchased by a variety of institutional investors in the last quarter, including Deutsche Bank AG, State Street Corp, Tang Capital Management LLC, Acadian Asset Management LLC, Skandinaviska Enskilda Banken AB publ , Skandinaviska Enskilda Banken AB publ , Federated Hermes Inc., and Pictet Asset Management Ltd.. View insider buying and selling activity for Vanda Pharmaceuticals.

Shares of VNDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VNDA stock can currently be purchased for approximately $11.46.

Vanda Pharmaceuticals has a market capitalization of $625.14 million and generates $227.19 million in revenue each year. The biopharmaceutical company earns $115.55 million in net income (profit) each year or $2.11 on an earnings per share basis. Vanda Pharmaceuticals employs 270 workers across the globe.

The official website for Vanda Pharmaceuticals is www.vandapharma.com.

Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE NW SUITE 300 E, WASHINGTON DC, 20037. The biopharmaceutical company can be reached via phone at 202-734-3400 or via email at [email protected]